Pharma Pulse 3/4/25: How to Mitigate a Potential Drop in Demand Due to Tariffs, What ‘Going Wild’ on Healthcare Could Mean & more
The latest news for pharma industry insiders.
How Pharmaceutical Companies Can Mitigate a Potential Drop in Demand Due to Tariffs
In this part of his Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, identifies strategies that pharmaceutical companies and digital health platforms can employ to navigate a potential drop in demand due to tariff-induced increased costs.
What ‘Going Wild’ on Healthcare Could Mean: The Early Days of Trump Healthcare
Three Washington, D.C., healthcare policy experts and the former chief of staff of HHS dive into the healthcare politics and policies of the new administration: RFK Jr.’s confirmation hearings; the future of IRA drug price negotiations and PBM reform; Medicare Advantage under the new administration; DOGE cuts at HHS; and ant-DEI and the social determinants of health.
AbbVie Enters Obesity Market With Up to $2.2 Billion Gubra Deal
AbbVie Inc. agreed to pay as much as $2.2 billion for a next-generation obesity drug from Danish biotech Gubra A/S, marking its entry into the hyper-competitive weight-loss market.
GenieMD and Tenovi have joined forces to enhance access to care through transformative virtual care models. The collaboration debuts with the Tenovi Pillbox, empowering individuals managing chronic conditions and their caregivers with real-time medication adherence tracking from home.
🗞️ The latest development in the tariff news - after an initial 30-day pause, President Trump plans to re-enact the import taxes on the nation’s trading partners—while also doubling the 10% tariff on China.
You can find continuous updates of the situation, along with the latest news and insights, via Pharmaceutical Commerce Magazine. ⬇️
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
